244 related articles for article (PubMed ID: 33811444)
1. A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.
Bolli R; Mitrani RD; Hare JM; Pepine CJ; Perin EC; Willerson JT; Traverse JH; Henry TD; Yang PC; Murphy MP; March KL; Schulman IH; Ikram S; Lee DP; O'Brien C; Lima JA; Ostovaneh MR; Ambale-Venkatesh B; Lewis G; Khan A; Bacallao K; Valasaki K; Longsomboon B; Gee AP; Richman S; Taylor DA; Lai D; Sayre SL; Bettencourt J; Vojvodic RW; Cohen ML; Simpson L; Aguilar D; Loghin C; Moyé L; Ebert RF; Davis BR; Simari RD;
Eur J Heart Fail; 2021 Apr; 23(4):661-674. PubMed ID: 33811444
[TBL] [Abstract][Full Text] [Related]
2. Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit
Bolli R; Hare JM; March KL; Pepine CJ; Willerson JT; Perin EC; Yang PC; Henry TD; Traverse JH; Mitrani RD; Khan A; Hernandez-Schulman I; Taylor DA; DiFede DL; Lima JAC; Chugh A; Loughran J; Vojvodic RW; Sayre SL; Bettencourt J; Cohen M; Moyé L; Ebert RF; Simari RD;
Circ Res; 2018 Jun; 122(12):1703-1715. PubMed ID: 29703749
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial.
Mathiasen AB; Qayyum AA; Jørgensen E; Helqvist S; Kofoed KF; Haack-Sørensen M; Ekblond A; Kastrup J
Eur J Heart Fail; 2020 May; 22(5):884-892. PubMed ID: 31863561
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial).
Mathiasen AB; Qayyum AA; Jørgensen E; Helqvist S; Fischer-Nielsen A; Kofoed KF; Haack-Sørensen M; Ekblond A; Kastrup J
Eur Heart J; 2015 Jul; 36(27):1744-53. PubMed ID: 25926562
[TBL] [Abstract][Full Text] [Related]
5. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial.
Hare JM; Fishman JE; Gerstenblith G; DiFede Velazquez DL; Zambrano JP; Suncion VY; Tracy M; Ghersin E; Johnston PV; Brinker JA; Breton E; Davis-Sproul J; Schulman IH; Byrnes J; Mendizabal AM; Lowery MH; Rouy D; Altman P; Wong Po Foo C; Ruiz P; Amador A; Da Silva J; McNiece IK; Heldman AW; George R; Lardo A
JAMA; 2012 Dec; 308(22):2369-79. PubMed ID: 23117550
[TBL] [Abstract][Full Text] [Related]
6. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.
Heldman AW; DiFede DL; Fishman JE; Zambrano JP; Trachtenberg BH; Karantalis V; Mushtaq M; Williams AR; Suncion VY; McNiece IK; Ghersin E; Soto V; Lopera G; Miki R; Willens H; Hendel R; Mitrani R; Pattany P; Feigenbaum G; Oskouei B; Byrnes J; Lowery MH; Sierra J; Pujol MV; Delgado C; Gonzalez PJ; Rodriguez JE; Bagno LL; Rouy D; Altman P; Foo CW; da Silva J; Anderson E; Schwarz R; Mendizabal A; Hare JM
JAMA; 2014 Jan; 311(1):62-73. PubMed ID: 24247587
[TBL] [Abstract][Full Text] [Related]
7. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
Chung ES; Miller L; Patel AN; Anderson RD; Mendelsohn FO; Traverse J; Silver KH; Shin J; Ewald G; Farr MJ; Anwaruddin S; Plat F; Fisher SJ; AuWerter AT; Pastore JM; Aras R; Penn MS
Eur Heart J; 2015 Sep; 36(33):2228-38. PubMed ID: 26056125
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
Bartolucci J; Verdugo FJ; González PL; Larrea RE; Abarzua E; Goset C; Rojo P; Palma I; Lamich R; Pedreros PA; Valdivia G; Lopez VM; Nazzal C; Alcayaga-Miranda F; Cuenca J; Brobeck MJ; Patel AN; Figueroa FE; Khoury M
Circ Res; 2017 Oct; 121(10):1192-1204. PubMed ID: 28974553
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review and Meta-Analysis: Safety and Efficacy of Mesenchymal Stem Cells Therapy for Heart Failure.
Shen T; Xia L; Dong W; Wang J; Su F; Niu S; Wang Q; Fang Y
Curr Stem Cell Res Ther; 2021; 16(3):354-365. PubMed ID: 32867655
[TBL] [Abstract][Full Text] [Related]
10. Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure.
Qayyum AA; Mouridsen M; Nilsson B; Gustafsson I; Schou M; Nielsen OW; Hove JD; Mathiasen AB; Jørgensen E; Helqvist S; Joshi FR; Johansen EM; Follin B; Juhl M; Højgaard LD; Haack-Sørensen M; Ekblond A; Kastrup J
ESC Heart Fail; 2023 Apr; 10(2):1170-1183. PubMed ID: 36638837
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial).
Mathiasen AB; Jørgensen E; Qayyum AA; Haack-Sørensen M; Ekblond A; Kastrup J
Am Heart J; 2012 Sep; 164(3):285-91. PubMed ID: 22980293
[TBL] [Abstract][Full Text] [Related]
12. Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trial.
Qayyum AA; van Klarenbosch B; Frljak S; Cerar A; Poglajen G; Traxler-Weidenauer D; Nadrowski P; Paitazoglou C; Vrtovec B; Bergmann MW; Chamuleau SAJ; Wojakowski W; Gyöngyösi M; Kraaijeveld A; Hansen KS; Vrangbaek K; Jørgensen E; Helqvist S; Joshi FR; Johansen EM; Follin B; Juhl M; Højgaard LD; Mathiasen AB; Ekblond A; Haack-Sørensen M; Kastrup J;
Eur J Heart Fail; 2023 Apr; 25(4):576-587. PubMed ID: 36644821
[TBL] [Abstract][Full Text] [Related]
13. Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial.
Bolli R; Hare JM; Henry TD; Lenneman CG; March KL; Miller K; Pepine CJ; Perin EC; Traverse JH; Willerson JT; Yang PC; Gee AP; Lima JA; Moyé L; Vojvodic RW; Sayre SL; Bettencourt J; Cohen M; Ebert RF; Simari RD;
Am Heart J; 2018 Jul; 201():54-62. PubMed ID: 29910056
[TBL] [Abstract][Full Text] [Related]
14. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.
Perin EC; Willerson JT; Pepine CJ; Henry TD; Ellis SG; Zhao DX; Silva GV; Lai D; Thomas JD; Kronenberg MW; Martin AD; Anderson RD; Traverse JH; Penn MS; Anwaruddin S; Hatzopoulos AK; Gee AP; Taylor DA; Cogle CR; Smith D; Westbrook L; Chen J; Handberg E; Olson RE; Geither C; Bowman S; Francescon J; Baraniuk S; Piller LB; Simpson LM; Loghin C; Aguilar D; Richman S; Zierold C; Bettencourt J; Sayre SL; Vojvodic RW; Skarlatos SI; Gordon DJ; Ebert RF; Kwak M; Moyé LA; Simari RD;
JAMA; 2012 Apr; 307(16):1717-26. PubMed ID: 22447880
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy.
Tompkins BA; Rieger AC; Florea V; Banerjee MN; Natsumeda M; Nigh ED; Landin AM; Rodriguez GM; Hatzistergos KE; Schulman IH; Hare JM
J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 30005555
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy.
Karantalis V; Suncion-Loescher VY; Bagno L; Golpanian S; Wolf A; Sanina C; Premer C; Kanelidis AJ; McCall F; Wang B; Balkan W; Rodriguez J; Rosado M; Morales A; Hatzistergos K; Natsumeda M; Margitich I; Schulman IH; Gomes SA; Mushtaq M; DiFede DL; Fishman JE; Pattany P; Zambrano JP; Heldman AW; Hare JM
J Am Coll Cardiol; 2015 Nov; 66(18):1990-1999. PubMed ID: 26516002
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE).
Paitazoglou C; Bergmann MW; Vrtovec B; Chamuleau SAJ; van Klarenbosch B; Wojakowski W; Michalewska-Włudarczyk A; Gyöngyösi M; Ekblond A; Haack-Sørensen M; Jaquet K; Vrangbaek K; Kastrup J;
Eur J Heart Fail; 2019 Aug; 21(8):1032-1041. PubMed ID: 30790396
[TBL] [Abstract][Full Text] [Related]
18. Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.
Borow KM; Yaroshinsky A; Greenberg B; Perin EC
Circ Res; 2019 Jul; 125(3):265-281. PubMed ID: 31318648
[TBL] [Abstract][Full Text] [Related]
19. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction.
Williams AR; Hatzistergos KE; Addicott B; McCall F; Carvalho D; Suncion V; Morales AR; Da Silva J; Sussman MA; Heldman AW; Hare JM
Circulation; 2013 Jan; 127(2):213-23. PubMed ID: 23224061
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
